Breaking News, Financial News

Financial Report: PDL BioPharma

Revenues up 18% in the quarter

PDL BioPharma

4Q Revenues: $86.0 million (+18%)

4Q Earnings: $49.4 million (+27%)

FY Revenues: $374.5 million (+3%)

FY Earnings: $211.7 million (+6%)

Comments: Growth in the quarter was primarily driven by increased royalties from sales of Herceptin and Avastin, which are marketed by Genentech and Roche. Royalty revenues for the year were up 7%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters